A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis

M. Boers, F. Buttgereit

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1435-1437
JournalRheumatology
Volume52
Issue number8
DOIs
Publication statusPublished - 2013

Cite this